96 related articles for article (PubMed ID: 34003767)
1. HIF1α or HIF2α: Enhancing CD8
Chen J
Cancer Immunol Res; 2021 Apr; 9(4):364. PubMed ID: 34003767
[TBL] [Abstract][Full Text] [Related]
2. Modified Hypoxia-Inducible Factor Expression in CD8
Veliça P; Cunha PP; Vojnovic N; Foskolou IP; Bargiela D; Gojkovic M; Rundqvist H; Johnson RS
Cancer Immunol Res; 2021 Apr; 9(4):401-414. PubMed ID: 33602720
[TBL] [Abstract][Full Text] [Related]
3. Reinforce the antitumor activity of CD8
Nabe S; Yamada T; Suzuki J; Toriyama K; Yasuoka T; Kuwahara M; Shiraishi A; Takenaka K; Yasukawa M; Yamashita M
Cancer Sci; 2018 Dec; 109(12):3737-3750. PubMed ID: 30302856
[TBL] [Abstract][Full Text] [Related]
4. Metabolic Control of CD8
Zhang L; Romero P
Trends Mol Med; 2018 Jan; 24(1):30-48. PubMed ID: 29246759
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-33, a Potential Cytokine Expressed in Tumor Microenvironment Involves in Antitumor Immunotherapy Through Facilitates CD8
Li X; Lv Q; Feng Y; Gu Y; Xia R; Ma J; He H; Zhu Y
J Interferon Cytokine Res; 2018 Nov; 38(11):491-499. PubMed ID: 30452317
[TBL] [Abstract][Full Text] [Related]
6. The Roles of CD8
St Paul M; Ohashi PS
Trends Cell Biol; 2020 Sep; 30(9):695-704. PubMed ID: 32624246
[TBL] [Abstract][Full Text] [Related]
7. A
Kjaergaard J; Hatfield S; Jones G; Ohta A; Sitkovsky M
J Immunol; 2018 Jul; 201(2):782-791. PubMed ID: 29802128
[TBL] [Abstract][Full Text] [Related]
8. Sialic Acid Blockade Suppresses Tumor Growth by Enhancing T-cell-Mediated Tumor Immunity.
Büll C; Boltje TJ; Balneger N; Weischer SM; Wassink M; van Gemst JJ; Bloemendal VR; Boon L; van der Vlag J; Heise T; den Brok MH; Adema GJ
Cancer Res; 2018 Jul; 78(13):3574-3588. PubMed ID: 29703719
[TBL] [Abstract][Full Text] [Related]
9. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression.
Huang H; Li F; Gordon JR; Xiang J
Cancer Res; 2002 Apr; 62(7):2043-51. PubMed ID: 11929823
[TBL] [Abstract][Full Text] [Related]
10. Adoptive CD8
Jiang X; Xu J; Liu M; Xing H; Wang Z; Huang L; Mellor AL; Wang W; Wu S
Cancer Lett; 2019 Oct; 462():23-32. PubMed ID: 31356845
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy Expands and Maintains the Function of High-Affinity Tumor-Infiltrating CD8 T Cells In Situ.
Moran AE; Polesso F; Weinberg AD
J Immunol; 2016 Sep; 197(6):2509-21. PubMed ID: 27503208
[TBL] [Abstract][Full Text] [Related]
12. CX3CR1-CD8+ T cells are critical in antitumor efficacy but functionally suppressed in the tumor microenvironment.
Yamauchi T; Hoki T; Oba T; Saito H; Attwood K; Sabel MS; Chang AE; Odunsi K; Ito F
JCI Insight; 2020 Apr; 5(8):. PubMed ID: 32255766
[TBL] [Abstract][Full Text] [Related]
13. Recruitment of host CD8+ T cells by tumor-infiltrating lymphocytes and recombinant interleukin-2 during adoptive immunotherapy of cancer.
Burger UL; Chang MP; Goedegebuure PS; Eberlein TJ; Adams-Hodgins S
Surgery; 1995 Mar; 117(3):325-33. PubMed ID: 7878540
[TBL] [Abstract][Full Text] [Related]
14. Toward improved immunocompetence of adoptively transferred CD8+ T cells.
Speiser DE; Romero P
J Clin Invest; 2005 Jun; 115(6):1467-9. PubMed ID: 15931384
[TBL] [Abstract][Full Text] [Related]
15. Concurrent induction of CD4+ and CD8+ T cells during tumor growth with antitumor reactivity in adoptive immunotherapy.
Arca MJ; Krauss JC; Aruga A; Cameron MJ; Chang AE
J Immunother; 1997 Mar; 20(2):138-45. PubMed ID: 9087386
[TBL] [Abstract][Full Text] [Related]
16. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
[TBL] [Abstract][Full Text] [Related]
17. Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice.
Contreras A; Sen S; Tatar AJ; Mahvi DA; Meyers JV; Srinand P; Suresh M; Cho CS
Cancer Immunol Immunother; 2016 May; 65(5):601-11. PubMed ID: 27011014
[TBL] [Abstract][Full Text] [Related]
18. Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy.
Wei J; Long L; Zheng W; Dhungana Y; Lim SA; Guy C; Wang Y; Wang YD; Qian C; Xu B; Kc A; Saravia J; Huang H; Yu J; Doench JG; Geiger TL; Chi H
Nature; 2019 Dec; 576(7787):471-476. PubMed ID: 31827283
[TBL] [Abstract][Full Text] [Related]
19. Toward T Cell-Mediated Control or Elimination of HIV Reservoirs: Lessons From Cancer Immunology.
Mylvaganam G; Yanez AG; Maus M; Walker BD
Front Immunol; 2019; 10():2109. PubMed ID: 31552045
[TBL] [Abstract][Full Text] [Related]
20. Modeling the CD8+ T effector to memory transition in adoptive T-cell antitumor immunotherapy.
Rolle CE; Carrio R; Malek TR
Cancer Res; 2008 Apr; 68(8):2984-92. PubMed ID: 18413768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]